{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:22:11Z","timestamp":1787775731533,"version":"build-2784847793"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Drug-resistant tuberculosis (DR-TB) poses a significant threat to global TB control and remains a major public health issue. This study aims to evaluate treatment outcomes and identify risk factors for unfavorable outcomes in patients with multi-DR-TB (MDR-TB) treated at a major reference hospital in Istanbul.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 413 patients with rifampicin-resistant and MDR-TB who received treatment between January 1, 2013, and December 31, 2023, at the University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases Training and Research Hospital. Patients were treated following the World Health Organization and national guidelines, with regimens tailored to individual drug resistance profiles and side effect management. Demographic data, comorbidities, microbiological follow-up, drug resistance patterns, treatment regimens, and radiological findings were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Treatment success was achieved in 350 patients (84.74%). Thirty-two patients (7.74%) were lost to follow-up, and 32 patients (7.74%) died. Logistic regression analysis identified several factors associated with unfavorable treatment outcomes: comorbidities (odds ratio [OR]: 7.555,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001), quinolone resistance (OR: 3.695,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.030), and bronchiectasis (OR: 4.126,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013). Additional significant factors included male gender (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007), foreign-born status (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.013), age over 35 years (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), previous treatment history (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.058), and drug side effects (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The long-term regimen for MDR-TB was found to be highly successful, with an 84.74% treatment success rate. Effective treatment regimens, close patient follow-up, early recognition of side effects, and comprehensive management are crucial for achieving successful outcomes. Identifying and addressing risk factors such as comorbidities, drug resistance, and specific patient demographics can further improve treatment success rates. This study underscores the importance of tailored treatment strategies and robust patient management in combating MDR-TB.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_132_24","type":"journal-article","created":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T16:00:41Z","timestamp":1726416041000},"page":"265-274","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Affecting Factors Unfavorable Treatment Outcomes of Rifampicin-resistant\/Multidrug-resistant Tuberculosis Patients Treated with Long-term Regimen"],"prefix":"10.4103","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-1558","authenticated-orcid":false,"given":"Aylin","family":"Babalik","sequence":"first","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Balik\u00e7i","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"Turkar","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazli Huma","family":"Teke","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma K\u00fcbra","family":"Demir","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simge","family":"Yavuz","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Nur","family":"Ko\u00e7","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senem","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fc\u015fra","family":"Erge\u00e7","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Can","family":"Alag\u00f6z","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eren","family":"Sario\u011flu","sequence":"additional","affiliation":[{"name":"University of Health Sciences S\u00fcreyyapa\u015fa Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeki","family":"Kili\u00e7aslan","sequence":"additional","affiliation":[{"name":"Chest Disease, Istanbul University, Istanbul Faculty of Medicine, Istanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"R1-20241212","article-title":"Tuberculosis Fight in Turkey 2021 Report"},{"key":"R3-20241212","article-title":"Ministry of Health Tuberculosis Diagnosis and Treatment Guideline 2019, Ankara"},{"key":"R6-20241212","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"R7-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","article-title":"Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review","volume":"12","author":"Putra","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R8-20241212","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/ijmy.ijmy_57_21","article-title":"Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-Western Nigeria","volume":"10","author":"Dayyab","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R9-20241212","doi-asserted-by":"crossref","first-page":"372","DOI":"10.4103\/ijmy.ijmy_143_23","article-title":"A critical review of risk factors influencing the prevalence of extensive drug-resistant tuberculosis in India","volume":"12","author":"Khan","year":"2023","journal-title":"Int J Mycobacteriol"},{"key":"R10-20241212","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4103\/ijmy.ijmy_170_20","article-title":"Pattern of primary tuberculosis drug resistance and associated risk factors at Dubai health authority in Dubai","volume":"9","author":"Habous","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R11-20241212","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/ijmy.ijmy_116_20","article-title":"High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India","volume":"9","author":"Chaubey","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R12-20241212","doi-asserted-by":"crossref","first-page":"100398","DOI":"10.1016\/j.jctube.2023.100398","article-title":"Survival status and risk factors for mortality among multidrug-resistant tuberculosis patients in Addis Ababa, Ethiopia: A retrospective follow-up study","volume":"33","author":"Getahun","year":"2023","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"R13-20241212","doi-asserted-by":"crossref","first-page":"e0256773","DOI":"10.1371\/journal.pone.0256773","article-title":"Comparison of profile and treatment outcomes between elderly and non-elderly tuberculosis patients in Puducherry and Tamil Nadu, South India","volume":"16","author":"Murali","year":"2021","journal-title":"PLoS One"},{"key":"R14-20241212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/ijmy.ijmy_219_23","article-title":"Analysis of the outcomes of tuberculosis treatment and factors associated with successful treatment at the Bamenda Regional Hospital: A 10-year retrospective study","volume":"13","author":"Chethkwo","year":"2024","journal-title":"Int J Mycobacteriol"},{"key":"R15-20241212","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.5588\/ijtld.18.0596","article-title":"Multidrug-resistant tuberculosis in Lisbon: Unfavourable treatment and associated factors, 2000-2014","volume":"23","author":"Bhering","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"R16-20241212","doi-asserted-by":"crossref","first-page":"e010592","DOI":"10.1136\/bmjgh-2022-010592","article-title":"Prevalence and predictive factors of tuberculosis treatment interruption in the Asia region: A systematic review and meta-analysis","volume":"8","author":"Oh","year":"2023","journal-title":"BMJ Glob Health"},{"key":"R17-20241212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2147\/IDR.S397304","article-title":"A scoring system based on laboratory parameters and clinical features to predict unfavorable treatment outcomes in multidrug- and rifampicin-resistant tuberculosis patients","volume":"16","author":"Yan","year":"2023","journal-title":"Infect Drug Resist"},{"key":"R18-20241212","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.2147\/IJGM.S428962","article-title":"Computed tomography manifestations in patients with rifampin primary drug-resistant tuberculosis in an infectious disease hospital in the Yi Autonomous Prefecture, China","volume":"16","author":"Wang","year":"2023","journal-title":"Int J Gen Med"},{"key":"R19-20241212","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4103\/ijmy.ijmy_160_21","article-title":"Incidence of adverse drug events among patients on second line anti-tuberculosis regimen in the littoral region of cameroon","volume":"10","author":"Mbuh","year":"2021","journal-title":"Int J Mycobacteriol"},{"key":"R20-20241212","doi-asserted-by":"crossref","first-page":"20503121231171350","DOI":"10.1177\/20503121231171350","article-title":"Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda","volume":"11","author":"Kushemererwa","year":"2023","journal-title":"SAGE Open Med"},{"key":"R21-20241212","doi-asserted-by":"crossref","first-page":"2332878","DOI":"10.1080\/20523211.2024.2332878","article-title":"Frequency, management and impact of adverse events on treatment outcomes in patients with multidrug resistant tuberculosis in Balochistan, Pakistan","volume":"17","author":"Rafique","year":"2024","journal-title":"J Pharm Policy Pract"},{"key":"R22-20241212","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R23-20241212","doi-asserted-by":"crossref","first-page":"790718","DOI":"10.3389\/fmed.2021.790718","article-title":"Frequency and factors associated with adverse events among multi-drug resistant tuberculosis patients in Pakistan: A retrospective study","volume":"8","author":"Atif","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R24-20241212","doi-asserted-by":"crossref","first-page":"e0255357","DOI":"10.1371\/journal.pone.0255357","article-title":"Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam","volume":"16","author":"Ngoc","year":"2021","journal-title":"PLoS One"},{"key":"R25-20241212","doi-asserted-by":"crossref","first-page":"e0255357","DOI":"10.1371\/journal.pone.0255357","article-title":"Active surveillance for adverse events in patients on longer treatment regimens for multidrug-resistant tuberculosis in Viet Nam","volume":"16","author":"Ngoc","year":"2021","journal-title":"PLoS One"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_132_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:40:32Z","timestamp":1787773232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_132_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_132_24","relation":{},"ISSN":["2212-5531","2212-554X"],"issn-type":[{"value":"2212-5531","type":"print"},{"value":"2212-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"2024-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}